Skip to main content

NSDB Partners and Collaborators

Nanotechnology research is an interdisciplinary endeavor by nature. Investigators with basic science, engineering, molecular biology, and clinical backgrounds must collaborate in order to design new drugs and diagnostic tools that can improve patient outcomes.

The Nanodelivery Systems and Devices Branch is continually working with our private sector, academic, and government partners to advance the translation and research of nanotechnology-center solutions for cancer. Below are a list of a few recent efforts toward this end.


TONIC Federal Register Announcement

The Federal Register Announcement introducing TONIC.

The NCI has initiated a public-private industry partnership called Translation of Nanotechnology in Cancer (TONIC) to accelerate the translation and development of nanotechnology solutions for the early detection, diagnosis, and treatment of cancer. The TONIC consortium, made up of government entities, and pharmaceutical, biotechnology, and other healthcare-related companies, will work in parallel to the Alliance. The consortium seeks to evaluate promising nanotechnology platforms and facilitate their successful translation from academic research to the clinic, resulting in safe, timely, effective, and novel diagnosis and treatment options for patients.

By encouraging mutual collaborations between Alliance investigators and industry partners on both pre-competitive and late-stage programs, TONIC stands to promote the qualification, development, and regulatory acceptance of nanotechnologies in cancer.

Contact NSDB to learn about participating in TONIC.

Start-Up Challenge

The Center for Advancing Innovation and NCI have partnered to launch the Nanotechnology Startup Challenge in Cancer. This Challenge features inventions conceived and developed by scientists at the National Institutes of Health and is also open to teams that bring other promising cancer nano-technology inventions. The goal of the challenge is to accelerate and increase the volume of commercialized cancer nanotechnology by launching new startups.